SCHEMBL3524183

SCHEMBL3524183

CS(=O)(=O)c1nccc(-c2c(-c3ccc(F)cc3)nc3c(NC4CC4)nccn23)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 3/20 0.48
CDK2 P24941 3/20 0.48
CCNA2 P20248 2/20 0.48
CDK5 Q00535 2/20 0.48
CDK5R1 Q15078 2/20 0.48
CCNT1 O60563 1/20 0.48
CDK9 P50750 1/20 0.48
HASPIN Q8TF76 1/20 0.48
MAPK9 P45984 8/20 0.47
CSNK1D P48730 7/20 0.47
PRKD2 Q9BZL6 6/20 0.46
PRKD3 O94806 6/20 0.46
MAP4K4 O95819 6/20 0.46
CSNK1A1 P48729 6/20 0.46
TAOK1 Q7L7X3 6/20 0.46
CSNK1G2 P78368 5/20 0.46
MINK1 Q8N4C8 5/20 0.46
MAPK8 P45983 5/20 0.46
GSK3B P49841 4/20 0.46
MAPK1 P28482 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519582 0.84 CSNK1E (0.50) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL3519701 0.83 MAPK9 (0.58) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL27741879 0.83 CSNK1E (0.69) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL3522612 0.83 MAPK9 (0.58) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL3521273 0.82 MAPK9 (0.62) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL3524969 0.82 CSNK1E (0.71) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL3525694 0.80 CSNK1E (0.71) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL3523229 0.78 MAPK9 (0.64) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL3523115 0.78 CSNK1E (0.49) CSNK1ECDK2CCNA2CDK5CDK5R1
SCHEMBL3525223 0.78 GRIA1 (0.55) CSNK1ECDK2CCNA2CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709468-B2 Imidazo based heterocycles ABBOTT LABORATORIES (US) 2010-05-04 US disclosed
CN-101291582-A Novel imidazo based heterocycles ABBOTT LAB (US) 2008-10-22 CN disclosed
US-20070099925-A1 Novel imidazo based heterocycles ABBVIE INC. 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099925-A1 Novel imidazo based heterocycles CDK4, CDK2, MAP3K19 CSNK1E 216/4885CDK2 2/4885CCNA2 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.